Enarodustat with cyclosporine for transfusion-dependent aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a new drug called enarodustat, when combined with cyclosporine, can improve blood cell counts better than cyclosporine alone in people with transfusion-dependent non-severe aplastic anemia. If you qualify, you might need fewer transfusions and feel better overall.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a diagnosis of non-severe aplastic anemia that requires blood transfusions.
- You must not have a matched donor or be able to have a stem cell transplant as your first treatment.
- Your liver and kidneys should be working reasonably well (within normal limits).
- You should be fairly active and able to care for yourself (ECOG score 2 or less).
- You must not have had certain prior treatments (like ATG, cyclosporine, TPO-RA drugs, or roxadustat).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs to help your bone marrow make more blood cells if you have aplastic anemia and cannot have a stem cell transplant or standard immune therapy. It might improve blood counts and reduce the need for transfusions.
This study tests a drug called luspatercept for people with a mild form of aplastic anemia who still need frequent blood transfusions. Luspatercept may help your body make more red blood cells, reducing the need for transfusions and improving your energy.
This study tests a daily pill that helps people with chronic kidney disease and anemia make more red blood cells, which may reduce the need for other anemia treatments. It is for patients who are not on dialysis and do not plan to start dialysis or have a kidney transplant within the next six months.
This trial tests enarodustat, a pill for anemia, in people with chronic kidney disease who are not on dialysis. It aims to see if it can safely raise hemoglobin levels.
This trial tests whether a new combination of medicines can help treat severe aplastic anemia (SAA) or a related type (TD-NSAA). It uses a drug that helps your body make more platelets, along with immunosuppressants, and may offer an alternative if a bone marrow transplant isn't possible.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
Hear when a new Transfusion-dependent Non-severe Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.